Reviewer's report

Title: Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) Study

Version: 2 Date: 4 April 2013

Reviewer: vittorio martinelli

Reviewer's report:

The revisions made by the authors to the manuscript have substantially contributed to improve the quality of the data obtained from the Renew study. Only additional minor revisions may definitely make it suitable to publication:

• Are there any negative data on amenorrea related to cumulative dose?
• The detailed description of AE (Result section) might be shortened by eliminating in the text how many of them were considered related or not related to therapy by the PI (data have been also reported in Table 5).
• The same for the 12 deaths (data have been also reported in Table 7).
• I would cross out the paragraph related to the 12 deaths in the discussion.
• Since the patients received a mean of 6 infusions during the study period and the results showed that the cumulative dose of Mitoxantrone is the primary risk factor associated with cardiotoxicity (see Table 4, too), in the conclusion the authors should add a comment on the cumulative dose related toxicity (Renew data for cardiotoxicity and literature data for Leukemia), and a recommendation to use the lowest possible cumulative dose of Mitoxantrone. ( “Stay on-label, but anyway try to use the lowest possible cumulative dose”).

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests'